Ahmedabad: Drug controller general of India (DGCI) which was cautious in giving nod to the new virus like particle (VLP) technology for developing H1N1 vaccine earlier this year, says the vaccine will get an approval.
"The VLP technology based vaccine will be approved, but it will take some time," Drug Controller General of India Surinder Singh told reporters, on sidelines of an event here Saturday.
Singh was replying to a query whether the VLP based vaccine technology get an approval of the national drug regulator in India.
"There were some issues in regards to safety aspect of it (vaccine). Though its a virus like particle, it has got nothing to do with the virus as such. It is basically the protein part of it which needs to be looked into," Singh said.
"This is a technology which is going to be used for the second time in the world. Earlier, there was a cervical cancer vaccine based on this technology which was developed by two multinational pharma companies," Singh said.
"So this is the first time it is going to be used for any other product," he said.
City based Cadila Pharmaceuticals has proposed to indigenously develop the world`s first Influenza A HINI (swine flu) vaccine in collaboration with US-based Novavax based on VLP technology.
Last year, the company had applied for the drug regulator`s permission to conduct trials in India.